MedPath

Assesment of Dawa al-Blaghm on liver enzymes in patients with fatty liver

Not Applicable
Conditions
Fatty liver desease.
Nonalcoholic fatty liver disease (NAFLD)
Registration Number
IRCT2017073135415N1
Lead Sponsor
Vice chancellor for research, Qom University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
100
Inclusion Criteria

1- Non-Alcohol-Fatty Liver Detection (NAFLD-Based Ultrasonography) 2- Serum Liver Enzyme Levels above Normal 3- Age between 18 and 65 years. 4- Fill in the consent form for participation in the plan.
Exclusion criteria: 1. Patient's lack of consent to continue participating in the project. 2. Any allergy to the drug. 3. The occurrence of any new liver disease that requires the use of specific liver medicines. 4. Pregnancy.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Ast. Timepoint: On arrival, three months after taking a medication or placebo. Method of measurement: U / L, Spectrophotometer.;Alt. Timepoint: On arrival, three months after taking a medication or placebo. Method of measurement: U / L, Spectrophotometer.;Alkp. Timepoint: On arrival, three months after taking a medication or placebo. Method of measurement: U / L, Spectrophotometer.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath